Boston Scientific Reports Q2 2026 Earnings with Mixed Performance Across Business Units
Boston Scientific Corporation reported mixed results for its second quarter in 2026, driven by strong performance in Interventional Cardiology, Endoscopy, and Neuromodulation. However, the company faced challenges from a slowdown in the Left Atrial Appendage Closure (LAAC) market due to clinical concerns affecting patient referrals. The U.S. Electrophysiology segment underperformed as competition shifted faster than expected toward Pulsed Field Ablation (PFA). Meanwhile, most business units grew at their historical 6% rate, while the Urology division lagged behind expectations. Operational margins were negatively impacted by lower-margin sales and increased investments in supply chain improvements. Looking ahead, Boston Scientific revised its full-year revenue guidance to a range of 5-6%, citing ongoing challenges through 2027 before expecting recovery in 2028 with seven major product launches across $25 billion markets. A restructuring program aims for $500 million in savings by the end of 2029, and there are plans to potentially re-enter the TAVR market via its investment in MiRus.
Topics: Endoscopy Interventional Cardiology Medical Devices Neuromodulation Pulsed Field Ablation (PFA) Urology WATCHMAN Franchise